Immune Responses of Piglets Immunized by a Recombinant Plasmid Containing Porcine Circovirus Type 2 and Porcine Interleukin-18 Genes

Chen, Guanglei; Fu, Pengfei; Wang, Linqing; Li, Xinsheng; Chen, Hongying

doi:10.1089/vim.2014.0036

Cited by 4 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These Qm1-related IgG sera titers for the vaccinated piglets were higher than those reported for subcutaneously vaccinated mice with a PCV2-encoding VLP-based vaccine, with a 1:40,000 titer, as well as with the CircoFLEX ® vaccine, where the titer was below 1:10,000 [26]. A DNA vaccine, expressing the Cap protein for PCV2, also showed an increase in IgG in the sera of vaccinated piglets, however, the titer was not calculated and it is therefore not comparable with the results of this work [70].…”

Section: Protection Against Pcv2 Induced By the Qm1 Antigencontrasting

confidence: 93%

A Heterologous Viral Protein Scaffold for Chimeric Antigen Design: An Example PCV2 Virus Vaccine Candidate

Lamazares

Gutiérrez

Hidalgo

et al. 2020

Viruses

View full text Add to dashboard Cite

Recombinant vaccines have low-cost manufacturing, regulatory requirements, and reduced side effects compared to attenuated or inactivated vaccines. In the porcine industry, post-weaning multisystemic disease syndrome generates economic losses, characterized by progressive weight loss and weakness in piglets, and it is caused by porcine circovirus type 2 (PCV2). We designed a chimeric antigen (Qm1) to assemble the main exposed epitopes of the Cap-PCV2 protein on the capsid protein of the tobacco necrosis virus (TNV). This design was based on the Cap-N-terminal of an isolated PCV2 virus obtained in Chile. The virus was characterized, and the sequence was clustered within the PCV2 genotype b clade. This chimeric protein was expressed as inclusion bodies in both monomeric and multimeric forms, suggesting a high-molecular-weight aggregate formation. Pigs immunized with Qm1 elicited a strong and specific antibody response, which reduced the viral loads after the PCV2 challenge. In conclusion, the implemented design allowed for the generation of an effective vaccine candidate. Our proposal could be used to express the domains or fragments of antigenic proteins, whose structural complexity does not allow for low-cost production in Escherichia coli. Hence, other antigen domains could be integrated into the TNV backbone for suitable antigenicity and immunogenicity. This work represents new biotechnological strategies, with a reduction in the costs associated with vaccine development.

show abstract

Section: Protection Against Pcv2 Induced By the Qm1 Antigencontrasting

confidence: 93%

A Heterologous Viral Protein Scaffold for Chimeric Antigen Design: An Example PCV2 Virus Vaccine Candidate

Lamazares

Gutiérrez

Hidalgo

et al. 2020

Viruses

View full text Add to dashboard Cite

show abstract

“…In addition, DNA plasmid bearing PCV2 ORF2 gene has a protective effect against challenge with PCV2 in mice which could be promoted with the utilization of pIL-15.Fu [20] evaluated three adjuvants Ubiquitin (ub), the peptide binding truncated C-terminal portion of heat shock protein 70 (hsp70c) and interleukin-2 (IL-2) in PCV2 DNA vaccine, they found that ub is a superior adjuvant for PCV2 DNA vaccination than the hsp70c and IL-2 molecules. Chen [21] evaluated two recombinant plasmids containing the ORF2 gene of porcine circovirus type 2 (PCV2) with or without porcine interleukin-18 (IL-18) and found that the plasmid pBudCE4.1-ORF2/IL18 may be an effective approach for increasing the immunogenicity of PCV2 DNA vaccine.…”

Section: Discussionmentioning

confidence: 99%

Immunogenicity of porcine circovirus type 2 nucleic acid vaccine containing CpG motif for mice

et al. 2016

Virol J

View full text Add to dashboard Cite

BackgroundThis study aimed at reseaching the immune effect of porcine circovirus type 2 (PCV2) DNA vaccine containing CpG motif on mice.MethodsA total of 40 6-week-old female BALB/c mice were randomly divided into four groups which were immunized by 18CpG-pVAX1-ORF2, pVAX1-ORF2, pVAX1 and PBS, respectively, and immunized again 2 weeks later. All mice were challenged with 0.2 mL PCV2 cells virulent strain SD (106.0 TCID50/mL) after 4 weeks. Average daily gain, blood antibody levels, microscopic changes and viremia were detected to estimate the effect of DNA vaccine.Results and DiscussionThe results showed that compared to those of the control mice, groups immunized with pVAX1-ORF2 and 18CpG-pVAX1-ORF2 could induce PCV2-specific antibodies. The PCV2-specific antibodies level of 18 CpG-pVAX1-ORF2 groups was higher significantly than other groups and decreased slowly along with time. There was no distinct pathological damage and viremia occurring in mice that inoculated with CpG motif DNA vaccines. The results demonstrated that the DNA vaccine containing 18 CpG could build up resistibility immunity and reduce immune organ damage on mice.

show abstract

Ten years of PCV2 vaccines and vaccination: Is eradication a possibility?

Afghah

Webb

Meng

et al. 2017

Veterinary Microbiology

View full text Add to dashboard Cite

Immune Responses of Piglets Immunized by a Recombinant Plasmid Containing Porcine Circovirus Type 2 and Porcine Interleukin-18 Genes

Cited by 4 publications

References 37 publications

A Heterologous Viral Protein Scaffold for Chimeric Antigen Design: An Example PCV2 Virus Vaccine Candidate

A Heterologous Viral Protein Scaffold for Chimeric Antigen Design: An Example PCV2 Virus Vaccine Candidate

Immunogenicity of porcine circovirus type 2 nucleic acid vaccine containing CpG motif for mice

Ten years of PCV2 vaccines and vaccination: Is eradication a possibility?

Contact Info

Product

Resources

About